Update shared on 23 Nov 2025
Fair value Decreased 2.46%Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.
Analyst Commentary
Recent street research reveals a mix of optimism and caution among analysts following Becton Dickinson's latest results and updated forward guidance. Opinions diverge on the company's near- and longer-term outlook, with both supportive and skeptical insights emerging.
Bullish Takeaways
- Some analysts view the reduced forward guidance as a potential "reset," establishing a conservative baseline that could make future outperformance more achievable.
- Despite modest growth projections, the company is seen as positioning itself for a new phase of growth following the planned business separation in early 2026.
- The latest quarterly results modestly exceeded bottom-line expectations, suggesting operational resilience even amid headwinds.
- Bullish analysts maintain favorable ratings, highlighting Becton Dickinson's stability and execution track record within the medical technology sector.
Bearish Takeaways
- Several analysts express concern over the company's fiscal 2026 guidance, which projects low single digit growth and falls below consensus expectations.
- Ongoing challenges related to Alaris product comparisons, market conditions in China, and reduced vaccine sales are cited as key external pressures limiting near-term earnings growth.
- Bears see limited opportunities for meaningful earnings expansion prior to 2027, which impacts the company's valuation sentiment in the sector.
- Cautious outlooks lead to price target reductions, reflecting skepticism on the speed and magnitude of future recovery for Becton Dickinson.
What's in the News
- Duncan Regional Hospital became the first in the U.S. to implement BD Alaris EMR Interoperability with the MEDITECH EHR, expanding advanced infusion pump integration to all three major EHR systems. (Client Announcements)
- Becton Dickinson introduced the PureWick Portable Collection System, a battery-powered device designed to help wheelchair users manage urinary incontinence discreetly and maintain mobility. (Product-Related Announcements)
- The company received FDA clearance and CE marking in Europe for the Enteric Bacterial Panel and Enteric Bacterial Panelplus for the BD COR System. This provides rapid and comprehensive gastrointestinal infection testing. (Product-Related Announcements)
- BD announced a 1.0% increase in quarterly dividends, with a new rate of $1.05 per share payable December 2025. This raises the indicated annual dividend rate to $4.20 per share for fiscal 2026. (Dividend Increases)
- Becton Dickinson reported full enrollment of the iliac artery patient cohort in its pivotal AGILITY IDE study. This advances the evaluation of the Revello Vascular Covered Stent for peripheral arterial disease treatment. (Product-Related Announcements)
Valuation Changes
- Consensus Analyst Price Target has decreased from $206.58 to $201.49, reflecting a reduction in perceived fair value.
- Discount Rate has declined slightly from 8.57% to 8.49%, indicating a marginally lower implied risk premium.
- Revenue Growth expectations have decreased marginally from 2.64% to 2.63%.
- Net Profit Margin has increased slightly, moving from 11.81% to 11.81%.
- Future P/E ratio has edged down from 26.45x to 26.29x, suggesting a modest reduction in expected future earnings multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.